FDA Hints At Additional Trials for Acusphere’s Imagify
This article was originally published in The Pink Sheet Daily
Executive Summary
Stocks plummet after FDA posts briefing documents detailing extensive safety concerns, and problems with efficacy data, before advisory committee meeting.